Wall Street

Flush with cash, Pfizer buys Global Blood Therapeutics in $5.4 billion deal

Published by
Reuters UK

(Reuters) -Pfizer Inc is boosting its pipeline with a $5.4 billion deal for blood disorder drugmaker Global Blood Therapeutics, the latest in a series of acquisitions to combat a potential slowdown in COVID-19 products demand as cases fall. Pfizer said on Monday it will pay $68.50 per share, representing a premium of 7.3% to Global Blood stock’s Friday closing and a 42.7% premium to Thursday’s closing, before the Wall Street Journal reported that Pfizer was in advanced talks to acquire the company. Pfizer has enjoyed an unprecedented rise in sales since the global rollout of its COVID-19 vacci…

Read More

Share this Story
Load More Related Articles
Load More In Wall Street